Security key
640268306
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 89,689
- Total 13F value
- $6,589,969
- Share change
- -40,643
- SEC-reported price per share
- $69.81
- Number of holders
- 11
- Value change
- -$2,894,311
- Number of buys
- 6
- Number of sells
- 3
- Shares outstanding
- 28,687,922
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
11
Top holders
10
NKTR full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
NEKTAR THERAPEUTICS SEC filings
NEKTAR THERAPEUTICS company facts
Broader feeds
Reporting periods
Holder history for CUSIP 640268306
Recent filing periods:
Ownership snapshot
Top reported holders of NKTR - NEKTAR THERAPEUTICS - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
BIOTECHNOLOGY VALUE FUND L P
9.8%
Two Seas Capital LP
6.8%
SUSQUEHANNA SECURITIES, LLC
4%
EVENTIDE ASSET MANAGEMENT, LLC
3.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
15%
|
$331,302,473
4,303,188 shares
|
+$97,502,292 | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
9.8%
|
$205,394,256
2,852,698 shares
|
$0 | 31 Mar 2026 |
| Two Seas Capital LP |
13D/G
13F
Company
|
6.8%
|
$144,979,172
1,959,178 shares
|
$0 | 31 Mar 2026 |
| SUSQUEHANNA SECURITIES, LLC |
13D/G
G1 Execution Services, LLC
|
4%
|
$34,245,405
809,967 shares
|
-$18,006,925 | 31 Dec 2025 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13D/G
|
3.6%
|
$4,921,000
6,650,000 shares
|
$0 | 31 Dec 2024 |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
Millennium Management LLC
|
3%
|
$32,489,559
570,994 shares
|
-$20,590,346 | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
11
Shares
89,689
Rows available
11
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
207
Q2 2026 holders
11
Holder diff
-196
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend